随着我国经济的快速发展，环境污染问题越来越受到关注。企业作为污染的主要制造者，有责任承担环境保护的责任，并向利益相关者披露企业的环境会计信息。本文选择生物医药行业作为研究对象，利用润灵环球ESG责任评级数据统计，选取了不同评级的生物医药上市公司作为样本，通过巨潮资讯网寻找相应资料，从生物医药行业环境会计信息披露方式和信息披露质量两个方面进行定量分析。通过对披露信息的赋分，分析了不同评级的生物医药行业环境会计信息披露现状以及存在的主要问题，提出了解决生物医药行业环境会计信息披露问题的建议。本文的研究结果不仅可以为利益相关者提供决策帮助，也能够提高医药行业的社会形象。

As China's economy continues to develop rapidly, environmental pollution is receiving increasing attention. As the main polluters, enterprises have a responsibility to assume environmental protection obligations and disclose their environmental accounting information to stakeholders. This article focuses on the biopharmaceutical industry, using the RunLing Global ESG responsibility rating data to select biopharmaceutical listed companies with different ratings as samples. By searching for relevant information on the Wisdom Database, quantitative analysis is conducted on two aspects: environmental accounting information disclosure methods and information disclosure quality in the biopharmaceutical industry. By assigning scores to the disclosed information, the current status of environmental accounting information disclosure in the biopharmaceutical industry and the main problems that exist are analyzed. This article proposes suggestions for solving the environmental accounting information disclosure problem in the biopharmaceutical industry, which not only provides decision-making assistance for stakeholders but also enhances the social image of the pharmaceutical industry.